Green light for cancer drugs developed by AI specialist Owkin

AI company gets its breast and colorectal cancer therapies approved for use in Europe

AI biotech company Owkin has announced that two rapid and affordable AI-based diagnostic solutions designed to improve outcomes for breast and colorectal cancer patients have been approved for use in Europe.

Owkin’s RlapsRisk BC and MSIntuit CRC have received approval for diagnostic use throughout the European Union. By using AI to analyze digital images of pathology, they are designed to help clinicians make precision medicine more accessible to more patients at an early stage of their disease.

RlapsRisk BC becomes the first CE-IVD-approved digital pathology-based AI diagnostic that predicts relapse risk for patients with early breast cancer. Meanwhile, MSIntuit CRC is the first CE-IVD approved AI solution that enables the identification of stable microsatellite patients from routine histology slides, enabling a significant reduction in the number of diagnostic tests to detect the disease. microsatellite instability (MSI) in clinical practice.

These are the first approved diagnostic products developed by Owkin, which aims to develop further biomarker screening and outcome prediction diagnostics in a range of disease areas. The company’s mission is to combine patient care with medical research to discover new disease mechanisms and achieve better treatments for unmet medical needs.

Meriem Sefta, Head of Diagnostics at Owkin, explained: “Our mission is to use AI to find the right treatment for each patient. New drugs allow us to personalize treatments based on individual patient disease characteristics, promising a new era of precision medicine. But one hurdle doctors face is finding those patients quickly, accurately, and efficiently.

“Our first approved diagnostic solutions could help millions of breast and colorectal cancer patients get the treatments they need faster. This is a pivotal moment in Owkin’s mission to use AI to better understand diseases and develop more accurate diagnoses and treatments for patients,” she added.

Comments are closed.